menu
    • menu
    [{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Intratus","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"INT-11P001","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Glaukos \/ Glaukos","highestDevelopmentStatusID":"8","companyTruncated":"Glaukos \/ Glaukos"},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Attillaps Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"AchE","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Glaukos \/ Attillaps Holdings","highestDevelopmentStatusID":"4","companyTruncated":"Glaukos \/ Attillaps Holdings"},{"orgOrder":0,"company":"Glaukos","sponsor":"iVeena","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Copper Sulphate Pentahydrate","moa":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Glaukos \/ Glaukos","highestDevelopmentStatusID":"7","companyTruncated":"Glaukos \/ Glaukos"},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Travoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Travoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Celanese","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Travoprost","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Glaukos","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Glaukos"},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Travoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Stuart Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"ST-113","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Glaukos \/ Glaukos","highestDevelopmentStatusID":"5","companyTruncated":"Glaukos \/ Glaukos"},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Travoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Celanese","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Travoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Celanese","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ Celanese"},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Travoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NCX 1728","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Glaukos \/ Glaukos","highestDevelopmentStatusID":"14","companyTruncated":"Glaukos \/ Glaukos"},{"orgOrder":0,"company":"Glaukos","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Riboflavin","moa":"","graph1":null,"graph2":null,"graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Glaukos \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Glaukos \/ Not Applicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Ripple Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":null,"graph2":null,"graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Glaukos \/ Glaukos","highestDevelopmentStatusID":null,"companyTruncated":"Glaukos \/ Glaukos"}]

    Find Clinical Drug Pipeline Developments & Deals by Glaukos

    Menu

    Glaukos

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Glaukos Achieves Primary Endpoint in Phase 3 Epioxa™ Trial for Tolerability

                            Details : Epioxa (riboflavin) is a small molecule drug candidate, which is being evaluated for the treatment of patients with progressive keratoconus.

                            Brand Name : Epioxa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 16, 2024

                            Lead Product(s) : Riboflavin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Recipient : Ripple Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ripple Therapeutics Announces Evaluation and Licensing Agreements with Glaukos

                            Details : Under the term of license agreement, Glaukos will leverage Ripple's proprietary technology platform to create sustained release implants of targeted APIs for both glaucoma and retinal diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Recipient : Ripple Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NCX 1728

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : Nicox SA

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

                            Details : Under the license agreement, Glaukos will fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and other retinal diseases.

                            Brand Name : NCX 1728

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 23, 2024

                            Lead Product(s) : NCX 1728

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : Nicox SA

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

                            Details : iDose® TR (travoprost intracameral implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension.

                            Brand Name : iDose TR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 03, 2024

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Celanese

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Celanese Launches Glaukos' iDose TR Using VitalDose EVA

                            Details : iDose® TR (Travoprost Intracameral Implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension

                            Brand Name : iDose TR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 29, 2024

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Celanese

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

                            Details : iDose TR (travoprost intracameral implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).

                            Brand Name : iDose TR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 14, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ST-113

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Recipient : Stuart Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Stuart Therapeutics Announces Exclusive Worldwide License Agreement with Glaukos Corporation

                            Details : Under the agreement, Glaukos gains exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113, a synthesized collagen mimetic peptide, drug candidate for neuroprotection in glaucoma.

                            Brand Name : ST-113

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            October 18, 2023

                            Lead Product(s) : ST-113

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Recipient : Stuart Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Glaukos Announces FDA Acceptance of NDA Submission for iDose TR

                            Details : iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to dail...

                            Brand Name : iDose TR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 05, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Celanese

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Celanese Announces Agreement with Glaukos Corporation for Sustained Release Glaucoma Treatment

                            Details : Glaukos will supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR (travoprost), a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hy...

                            Brand Name : iDose TR

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 05, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Celanese

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Glaukos Submits New Drug Application to U.S. FDA for iDose TR

                            Details : iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to dail...

                            Brand Name : iDose TR

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 27, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth